Edward Stepanski
Research Subjects
Edward Stepanski has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Lee Steven Schwartzberg
Department of Internal Medicine, Renown Institute for Cancer and University of Nevada, Reno , Reno, NV
9 shared publications - Mark S. Walker
ConcertAI, LLC, Cambridge, MA 02138, USA
9 shared publications - Cameron M. Kaplan
University of Tennessee Health Science Center, Memphis, TN, USA
8 shared publications - Gregory A. Vidal
Clinical Research and Breast Oncology Program, Lee S Schwartzberg Research Center, West Cancer Center and Research Institute, Memphis, Tennessee
8 shared publications - Ilana Graetz
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA
8 shared publications - Michelle Y. Martin
Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, USA
8 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 2: List of HCPCS Codes to Identify Chemotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 2: List of HCPCS Codes to Identify Chemotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 4: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients with Surgery Date Identified
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 4: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients with Surgery Date Identified
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Figure 1: Sample selection flow chart. * Note: This figure shows how the study inclusion and exclusion criteria were applied to derive the final primary study cohort, and the additional criteria used for the subgroup cohorts included in sensitivity analyses. Each box represents one inclusion or exclusion criterion with the corresponding sample size. Abbreviations: PCM = Patient Care Monitor, FFS = Fee-For-Service
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Figure 1: Sample selection flow chart. * Note: This figure shows how the study inclusion and exclusion criteria were applied to derive the final primary study cohort, and the additional criteria used for the subgroup cohorts included in sensitivity analyses. Each box represents one inclusion or exclusion criterion with the corresponding sample size. Abbreviations: PCM = Patient Care Monitor, FFS = Fee-For-Service
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 3: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Medicare Beneficiaries Subsample
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 3: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Medicare Beneficiaries Subsample
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 1: List of Individual Symptoms Used Included in Composite Scores
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 1: List of Individual Symptoms Used Included in Composite Scores
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 5: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients Receiving At Least 4 Cycles of Chemotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Supplementary Table 5: Kitagawa-Blinder-Oaxaca Decomposition of Race Differences in one-SD Increases of Composite Scores among Patients Receiving At Least 4 Cycles of Chemotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Background:Symptom burden differences may contribute to racial disparities in breast cancer survival. We compared symptom changes from before to during chemotherapy among women with breast cancer.Methods:This observational study followed a cohort of Black and White women diagnosed with Stage I–III, hormone receptor–positive breast cancer from a large cancer center in 2007 to 2015, and reported symptoms before and during chemotherapy. We identified patients who experienced a one-standard deviation (SD) increase in symptom burden after starting chemotherapy using four validated composite scores (General Physical Symptoms, Treatment Side Effects, Acute Distress, and Despair). Kitagawa–Blinder–Oaxaca decomposition was used to quantify race differences in symptom changes explained by baseline characteristics (sociodemographic, baseline scores, cancer stage) and first-line chemotherapy regimens.Results:Among 1,273 patients, Black women (n = 405, 31.8%) were more likely to report one-SD increase in General Physical Symptoms (55.6% vs. 48.2%, P = 0.015), Treatment Side Effects (74.0% vs. 63.4%, P < 0.001), and Acute Distress (27.4% vs. 20.0%, P = 0.010) than White women. Baseline characteristics and first-line chemotherapy regimens explained a large and significant proportion of the difference in Acute Distress changes (93.7%, P = 0.001), but not General Physical Symptoms (25.7%, P = 0.25) or Treatment Side Effects (16.4%, P = 0.28).Conclusions:Black women with early-stage breast cancer were more likely to experience significant increases in physical and psychological symptom burden during chemotherapy. Most of the difference in physical symptom changes remained unexplained by baseline characteristics, which suggests inadequate symptom management among Black women.Impact:Future studies should identify strategies to improve symptom management among Black women and reduce differences in symptom burden.See related commentary by Rosenzweig and Mazanec, p. 157
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Background:Symptom burden differences may contribute to racial disparities in breast cancer survival. We compared symptom changes from before to during chemotherapy among women with breast cancer.Methods:This observational study followed a cohort of Black and White women diagnosed with Stage I–III, hormone receptor–positive breast cancer from a large cancer center in 2007 to 2015, and reported symptoms before and during chemotherapy. We identified patients who experienced a one-standard deviation (SD) increase in symptom burden after starting chemotherapy using four validated composite scores (General Physical Symptoms, Treatment Side Effects, Acute Distress, and Despair). Kitagawa–Blinder–Oaxaca decomposition was used to quantify race differences in symptom changes explained by baseline characteristics (sociodemographic, baseline scores, cancer stage) and first-line chemotherapy regimens.Results:Among 1,273 patients, Black women (n = 405, 31.8%) were more likely to report one-SD increase in General Physical Symptoms (55.6% vs. 48.2%, P = 0.015), Treatment Side Effects (74.0% vs. 63.4%, P < 0.001), and Acute Distress (27.4% vs. 20.0%, P = 0.010) than White women. Baseline characteristics and first-line chemotherapy regimens explained a large and significant proportion of the difference in Acute Distress changes (93.7%, P = 0.001), but not General Physical Symptoms (25.7%, P = 0.25) or Treatment Side Effects (16.4%, P = 0.28).Conclusions:Black women with early-stage breast cancer were more likely to experience significant increases in physical and psychological symptom burden during chemotherapy. Most of the difference in physical symptom changes remained unexplained by baseline characteristics, which suggests inadequate symptom management among Black women.Impact:Future studies should identify strategies to improve symptom management among Black women and reduce differences in symptom burden.See related commentary by Rosenzweig and Mazanec, p. 157
- 27 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (2) , 167-174
Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Background: Symptom burden differences may contribute to racial disparities in breast cancer survival. We compared symptom changes from before to during chemotherapy among women with breast cancer. Methods: This observational study followed a cohort of Black and White women diagnosed with Stage I–III, hormone receptor–positive breast cancer from a large cancer center in 2007 to 2015, and reported symptoms before and during chemotherapy. We identified patients who experienced a one-standard deviation (SD) increase in symptom burden after starting chemotherapy using four validated composite scores (General Physical Symptoms, Treatment Side Effects, Acute Distress, and Despair). Kitagawa–Blinder–Oaxaca decomposition was used to quantify race differences in symptom changes explained by baseline characteristics (sociodemographic, baseline scores, cancer stage) and first-line chemotherapy regimens. Results: Among 1,273 patients, Black women (n = 405, 31.8%) were more likely to report one-SD increase in General Physical Symptoms (55.6% vs. 48.2%, P = 0.015), Treatment Side Effects (74.0% vs. 63.4%, P < 0.001), and Acute Distress (27.4% vs. 20.0%, P = 0.010) than White women. Baseline characteristics and first-line chemotherapy regimens explained a large and significant proportion of the difference in Acute Distress changes (93.7%, P = 0.001), but not General Physical Symptoms (25.7%, P = 0.25) or Treatment Side Effects (16.4%, P = 0.28). Conclusions: Black women with early-stage breast cancer were more likely to experience significant increases in physical and psychological symptom burden during chemotherapy. Most of the difference in physical symptom changes remained unexplained by baseline characteristics, which suggests inadequate symptom management among Black women. Impact: Future studies should identify strategies to improve symptom management among Black women and reduce differences in symptom burden. See related commentary by Rosenzweig and Mazanec, p. 157
- 27 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (2) , 167-174
Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer
Background: Symptom burden differences may contribute to racial disparities in breast cancer survival. We compared symptom changes from before to during chemotherapy among women with breast cancer. Methods: This observational study followed a cohort of Black and White women diagnosed with Stage I–III, hormone receptor–positive breast cancer from a large cancer center in 2007 to 2015, and reported symptoms before and during chemotherapy. We identified patients who experienced a one-standard deviation (SD) increase in symptom burden after starting chemotherapy using four validated composite scores (General Physical Symptoms, Treatment Side Effects, Acute Distress, and Despair). Kitagawa–Blinder–Oaxaca decomposition was used to quantify race differences in symptom changes explained by baseline characteristics (sociodemographic, baseline scores, cancer stage) and first-line chemotherapy regimens. Results: Among 1,273 patients, Black women (n = 405, 31.8%) were more likely to report one-SD increase in General Physical Symptoms (55.6% vs. 48.2%, P = 0.015), Treatment Side Effects (74.0% vs. 63.4%, P < 0.001), and Acute Distress (27.4% vs. 20.0%, P = 0.010) than White women. Baseline characteristics and first-line chemotherapy regimens explained a large and significant proportion of the difference in Acute Distress changes (93.7%, P = 0.001), but not General Physical Symptoms (25.7%, P = 0.25) or Treatment Side Effects (16.4%, P = 0.28). Conclusions: Black women with early-stage breast cancer were more likely to experience significant increases in physical and psychological symptom burden during chemotherapy. Most of the difference in physical symptom changes remained unexplained by baseline characteristics, which suggests inadequate symptom management among Black women. Impact: Future studies should identify strategies to improve symptom management among Black women and reduce differences in symptom burden. See related commentary by Rosenzweig and Mazanec, p. 157
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 19102
Practice pattern for patients receiving secondline treatment for non-small cell lung cancer (NSCLC) with erlotinib in the community setting
19102 Background. Treatment of patients (pts) in clinical practice may vary from that on clinical trials. The objectives of this study were to characterize the clinical course of treatment, the rationale for treatment changes, and symptom burden for patients with NSCLC treated with erlotinib in community oncology clinics. Methods. A retrospective chart review was conducted at 4 community oncology sites in the US. Data were collected on 45 pts who received single agent erlotinib as either 2nd or 3rd line therapy for NSCLC between November 2004 and June 2007. Results. The sample was 44% female, 84% Caucasian (16% African American), with mean age of 66.7 (± 9.2). The mean # of cycles of erlotinib administered was 5.9 (± 6.4; range < 1–23). The mean # of clinic visits was 9.1 (± 9.0; range 1–43). Ten pts (22%) were hospitalized during erlotinib therapy, and 4 had multiple hospitalizations. 11 pts (24%) had a dose reduction while on erlotinib, and 13 (29%) had a dose delay. The most common reasons for dose reduction and delay were rash, diarrhea, and fatigue.32 pts (71%) received a carbo/taxane combination as first line therapy. The most common reasons for treatment discontinuation were: disease progression (53%), death (22%) and toxicity (11%; primarily appetite and GI symptoms). Conclusions. These results show that community practice patterns for use of erlotinib are generally consistent with data from the clinical trials literature. Older age and higher rate of dose reductions in pts receiving 2nd vs 3rd line treatment may reflect a selection of pts into the 2nd line group with worse performance status who were poor candidates for additional chemo.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 19102
Practice pattern for patients receiving secondline treatment for non-small cell lung cancer (NSCLC) with erlotinib in the community setting
19102 Background. Treatment of patients (pts) in clinical practice may vary from that on clinical trials. The objectives of this study were to characterize the clinical course of treatment, the rationale for treatment changes, and symptom burden for patients with NSCLC treated with erlotinib in community oncology clinics. Methods. A retrospective chart review was conducted at 4 community oncology sites in the US. Data were collected on 45 pts who received single agent erlotinib as either 2nd or 3rd line therapy for NSCLC between November 2004 and June 2007. Results. The sample was 44% female, 84% Caucasian (16% African American), with mean age of 66.7 (± 9.2). The mean # of cycles of erlotinib administered was 5.9 (± 6.4; range < 1–23). The mean # of clinic visits was 9.1 (± 9.0; range 1–43). Ten pts (22%) were hospitalized during erlotinib therapy, and 4 had multiple hospitalizations. 11 pts (24%) had a dose reduction while on erlotinib, and 13 (29%) had a dose delay. The most common reasons for dose reduction and delay were rash, diarrhea, and fatigue.32 pts (71%) received a carbo/taxane combination as first line therapy. The most common reasons for treatment discontinuation were: disease progression (53%), death (22%) and toxicity (11%; primarily appetite and GI symptoms). Conclusions. These results show that community practice patterns for use of erlotinib are generally consistent with data from the clinical trials literature. Older age and higher rate of dose reductions in pts receiving 2nd vs 3rd line treatment may reflect a selection of pts into the 2nd line group with worse performance status who were poor candidates for additional chemo.